FDA Becomes An Agency Of “Directorates” Under Hamburg’s Reorganization
This article was originally published in The Tan Sheet
Commissioner Margaret Hamburg’s structural reorganization of FDA leaves the current leadership of the agency’s centers intact, but adds a new layer of management and accountability between the medical product center directors and the commissioner’s office.
You may also be interested in...
Hamburg "Guardedly Optimistic" On FDA 2012 Budget; OMB Plans 2013 Cuts
FDA Commissioner Margaret Hamburg is "guardedly optimistic" the agency will retain its current funding level in fiscal 2012, but FDA and other agencies will expect 5% lower budgets for the following year.
Private Third-Party Audits Could Enhance FDA’s Manufacturing Risk Analysis
Private and third-party audits could direct FDA to problematic facilities while easing some inspection burden on firms that already comply, but not replace FDA’s typical inspection duties.
FDA Congressional Relations, Internal Structure May Change With Sharfstein Exit
The departure of Principal Deputy Commissioner Josh Sharfstein provides FDA an opportunity to take stock of its relationship with Congress and to re-evaluate its organizational structure.